
|Articles|December 3, 2018
Novel treatments in pipeline for diabetic eye disease
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.
Advertisement
Patrik De Haes, MD, CEO of Oxurion NV, shares the latest updates in clinical studies at the OIS@AAO meeting in Chicago, Oct. 2018.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
2
Q&A: Stephen Tsang discusses outcomes in retinitis pigmentosa and Stargardt trials
3
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
4
FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics
5

















































